Ads
related to: mixed hyperlipidemia treatment guidelines- Trial Results
See Clinical Data
and Trial
- Dosing & Administration
Efficacy, Safety, and Dosing
Information for HCPs
- Co-Pay Program
Resources
to Support Your Patients
- MOA
Mechanism of Action -
Watch A Video To Learn More
- Safety
Safety Profile - Learn About
Adverse Patient Reactions
- Patient Identification
View a Patient Profile
to Learn More
- Trial Results
Search results
Results From The WOW.Com Content Network
Hyperlipidemia happens when you have high levels of one or more lipids in your blood. ... Dyslipidemia Treatment. Dyslipidemia treatments vary depending on which lipids are too high or too low ...
Combined hyperlipidemia (or -aemia) is a commonly occurring form of hypercholesterolemia (elevated cholesterol levels) characterised by increased LDL and triglyceride concentrations, often accompanied by decreased HDL. [1]: 534 On lipoprotein electrophoresis (a test now rarely performed) it shows as a hyperlipoproteinemia type IIB. It is the ...
Hyperlipidemia is abnormally high levels of any or all lipids (e.g. fats, triglycerides, cholesterol, phospholipids) or lipoproteins in the blood. [2] The term hyperlipidemia refers to the laboratory finding itself and is also used as an umbrella term covering any of various acquired or genetic disorders that result in that finding. [3]
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug.In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [1]
Mixed hyperlipidemia, in combination with fenofibrate; Homozygous familial hypercholesterolemia, in combination with specific statins; Homozygous sitosterolemia; A 2018 review found that ezetimibe used as sole treatment slightly lowered plasma levels of lipoprotein(a), but the effect was not large enough to be important. [22]
Fenofibrate is mainly used for primary hypercholesterolemia or mixed dyslipidemia.Fenofibrate may slow the progression of diabetic retinopathy and the need for invasive treatment such as laser therapy in patients with type 2 diabetes with pre-existing retinopathy.
Ad
related to: mixed hyperlipidemia treatment guidelines